These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 6473092)

  • 21. Heparin and low-molecular-weight heparin.
    Gray E; Mulloy B; Barrowcliffe TW
    Thromb Haemost; 2008 May; 99(5):807-18. PubMed ID: 18449410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Characterization of a new potent heparin. 2nd communication: Chemical analysis of the carbohydrate content and determination of the biological activity of a new potent heparin preparation in vitro, using protamine neutralization and amidolytic methods for factor Xa and thrombin.
    Bhargava AS; Heinick J; Günzel P
    Arzneimittelforschung; 1980; 30(7):1071-4. PubMed ID: 7191289
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Product individuality of commercially available low-molecular-weight heparins and their generic versions: therapeutic implications.
    Maddineni J; Walenga JM; Jeske WP; Hoppensteadt DA; Fareed J; Wahi R; Bick RL
    Clin Appl Thromb Hemost; 2006 Jul; 12(3):267-76. PubMed ID: 16959680
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Inhibition of rat smooth muscle cell adhesion and proliferation by non-anticoagulant heparins.
    Kazi M; Lundmark K; Religa P; Gouda I; Larm O; Ray A; Swedenborg J; Hedin U
    J Cell Physiol; 2002 Dec; 193(3):365-72. PubMed ID: 12384988
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Separation of heparin into subfractions by DEAE-cellulose chromatography.
    Yue RH; Starr T; Gertler MM
    Thromb Haemost; 1980 Feb; 42(5):1452-9. PubMed ID: 7368152
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chromatographic analysis and sequencing approach of heparin oligosaccharides using cetyltrimethylammonium dynamically coated stationary phases.
    Mourier PA; Viskov C
    Anal Biochem; 2004 Sep; 332(2):299-313. PubMed ID: 15325299
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Are all low molecular weight heparins equivalent in the management of venous thromboembolism?
    Fareed J; Jeske W; Fareed D; Clark M; Wahi R; Adiguzel C; Hoppensteadt D
    Clin Appl Thromb Hemost; 2008 Oct; 14(4):385-92. PubMed ID: 18815137
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The use of an automated analyzer in the evaluation of antithrombin III and heparin.
    Scully MF
    Semin Thromb Hemost; 1983 Oct; 9(4):309-20. PubMed ID: 6658462
    [No Abstract]   [Full Text] [Related]  

  • 29. Selective N-desulfation of heparin with dimethyl sulfoxide containing water or methanol.
    Inoue Y; Nagasawa K
    Carbohydr Res; 1976 Jan; 46(1):87-95. PubMed ID: 1248016
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Low molecular weight heparins: structural differentiation by bidimensional nuclear magnetic resonance spectroscopy.
    Guerrini M; Guglieri S; Naggi A; Sasisekharan R; Torri G
    Semin Thromb Hemost; 2007 Jul; 33(5):478-87. PubMed ID: 17629844
    [TBL] [Abstract][Full Text] [Related]  

  • 31. [Contaminated heparins].
    Monneret C
    Ann Pharm Fr; 2008 Aug; 66(4):212-5. PubMed ID: 18847567
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Comparison of low molecular weight heparins and unfractionated heparin after successive subcutaneous administration. A randomized controlled study in healthy volunteers.
    Pindur G; Heiden M; Köhler M
    Arzneimittelforschung; 1993 May; 43(5):542-7. PubMed ID: 8392345
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Characterization of unfractionated heparin: comparison of materials from the last 50 years.
    Mulloy B; Gray E; Barrowcliffe TW
    Thromb Haemost; 2000 Dec; 84(6):1052-6. PubMed ID: 11154113
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Fondaparinux: a suitable alternative in cases of delayed-type allergy to heparins and semisynthetic heparinoids? A study of 7 cases.
    Jappe U; Juschka U; Kuner N; Hausen BM; Krohn K
    Contact Dermatitis; 2004 Aug; 51(2):67-72. PubMed ID: 15373846
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A meta-analysis of controlled clinical trials comparing low-molecular weight heparins with unfractionated heparin in unstable angina.
    Malhotra S; Karan RS; Bhargava VK; Pandhi P; Grover A; Sharma YP; Kumar R
    Indian Heart J; 2001; 53(2):197-202. PubMed ID: 11428477
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Treatment of venous thrombosis with low molecular weight heparin. Progress and outlook].
    Fiessinger JN
    Bull Acad Natl Med; 1997 May; 181(5):875-83; discussion 883-5. PubMed ID: 9312362
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Production method affects the pharmacokinetic and ex vivo biological properties of low molecular weight heparins.
    Brieger D; Dawes J
    Thromb Haemost; 1997 Feb; 77(2):317-22. PubMed ID: 9157589
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Examination of the heterogeneity of heparin. IV. Crude heparin].
    Jarzebiński J; Gryz K; Tońska S
    Acta Pol Pharm; 1993; 50(2-3):127-9. PubMed ID: 8030421
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A physical comparison of low molecular weight heparins prepared by different methods.
    Barlow GH; Petracek FJ
    Res Commun Chem Pathol Pharmacol; 1986 Aug; 53(2):241-4. PubMed ID: 3764086
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Heparin: from animal organ extract to designer drug.
    Middeldorp S
    Thromb Res; 2008; 122(6):753-62. PubMed ID: 17996279
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.